Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385298 | 0.93 | HPGDS (0.63) | HPGDSGPR119PRMT5THRBGAA | |
| SCHEMBL17065213 | 0.89 | HPGDS (0.50) | HPGDSPRMT5THRBSMN1; SMN2KDM4E | |
| SCHEMBL16054075 | 0.83 | HPGDS (0.45) | HPGDSGPR119MEN1KMT2AUSP30 | |
| SCHEMBL16054078 | 0.83 | HPGDS (0.45) | HPGDSGPR119MEN1KMT2AUSP30 | |
| SCHEMBL27752004 | 0.83 | HPGDS (0.43) | HPGDSPRMT5SMN1; SMN2MAPTPOLB | |
| SCHEMBL12580657 | 0.83 | GPR119 (0.52) | HPGDSGPR119THRBGAASMN1; SMN2 | |
| SCHEMBL1501747 | 0.82 | GPR119 (0.57) | HPGDSGPR119PRMT5THRBKDM4E | |
| SCHEMBL4343857 | 0.82 | HPGDS (0.55) | HPGDSGPR119PRMT5THRBGAA | |
| SCHEMBL4956602 | 0.82 | TSHR (0.47) | HPGDSMAPTMEN1KMT2AUSP30 | |
| SCHEMBL4956596 | 0.82 | TSHR (0.47) | HPGDSMAPTMEN1KMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059981-A9 | New Pyridine Analogues V | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20090318464-A1 | New Pyridine Analogues V | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| EP-2041115-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080032992-A1 | New Pyridine Analogues V | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| WO-2008004942-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318464-A1 | New Pyridine Analogues V | P2RY12, P2RY11, P2RY13 | HPGDS 506/4885GPR119 44/4885PRMT5 3292/4885 |
| US-20080032992-A1 | New Pyridine Analogues V | P2RY12, P2RY11, P2RY4 | HPGDS 401/4885GPR119 231/4885PRMT5 2640/4885 |
| US-20110059981-A9 | New Pyridine Analogues V | P2RY12, P2RY11, P2RY13 | HPGDS 506/4885GPR119 44/4885PRMT5 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.